Table 2.
Patient numbers and baseline demographic data for studies contributing to the population PK–PD model analysis
| Patient numbers | Demographic data Subjects used for analysis, mean ± SD (range) | |||||
|---|---|---|---|---|---|---|
| Study | Treated | Used in the analysis | Age (years) | Bodyweight (kg) | Baseline IgE (ng ml−1) | |
| Bioequivalence | 155 | 152 | 35 ± 12 (18–64) | 71 ± 12 (48–91) | 186 ± 124 (47–620) | |
| INNOVATE [13] | 482 core study 420 in follow-up (211 active, 209 placebo) | 440 226 active 214 placebo | Active | 42 ± 14 (12–79) | 79 ± 20 (45–143) | 509 ± 375 (51–1692) |
| Placebo | 43 ± 13 (14–74) | 77 ± 17 (39–146) | 479 ± 387 (53–2173) | |||
| [23] | 268 active | 268 active | Active | 39 ± 13 (12–73) | 80 ± 20 (39–150) | 417 ± 341 (48–2081) |
| 257 placebo | 257 placebo | Placebo | 39 ± 14 (12–74) | 78 ± 19 (39–136) | 451 ± 345 (51–1699) | |
| [24] | 274 active | 271 active | Active | 40 ± 15 (12–76) | 77 ± 17 (46–136) | 541 ± 411 (51–1900) |
| 272 placebo | 268 placebo | Placebo | 39 ± 14 (12–72) | 78 ± 18 (40–148) | 498 ± 391 (53–1970) | |
| [25] | 176 active | 133 active | Active | 44 ± 14 (12–73) | 76 ± 18 (41–135) | 578 ± 461 (63–2553) |
| 165 placebo | 144 placebo | Placebo | 43 ± 14 (12–74) | 74 ± 14 (41–115) | 605 ± 448 (46–1902) | |